Publications

Publications

Comparing efficiency of micro-RNA and mRNA biomarker liberation with microbubble-enhanced ultrasound exposure.

By:
Contributors: Robert Paproski, PhD
Ultrasound Med Biol. 2014 Sep;40(9):2207-16. doi: 10.1016/j.ultrasmedbio.2014.05.005. Epub 2014 Jul 9.

Abstract

Blood biomarkers are potentially powerful diagnostic tools that are limited clinically by low concentrations, the inability to determine biomarker origin and unknown patient baseline. Recently, ultrasound has been shown to liberate proteins and large mRNA biomarkers, overcoming many of these limitations. We have since demonstrated that adding lipid-stabilized microbubbles elevates mRNA concentration an order of magnitude compared with ultrasound without microbubbles, in vitro. Unfortunately the large size of some mRNA molecules may limit efficiency of release and hinder efficacy as an ultrasound-liberated biomarker. We hypothesize that smaller molecules will be released more efficiently with ultrasound than larger molecules. Although investigation of large libraries of biomarkers should be performed to fully validate this hypothesis, we focus on a small subset of mRNA and micro-RNAs. Specifically, we focus on miR-21 (22 base pairs [bp]), which is upregulated in certain forms of cancer, compared with previously investigated mammaglobin mRNA (502 bp). We also report release of micro-RNA miR-155 (22 bp) and housekeeping rRNA S18 (1869 bp). More than 10 million additional miR-21 copies per 100,000 cells are released with ultrasound-microbubble exposure. The low- molecular-weight miR-21 proved to be liberated 50 times more efficiently than high-molecular-weight mammaglobin mRNA, releasing orders of magnitude more miR-21 than mammaglobin mRNA under comparable conditions.

 PubMed

Download PDF

Thank you for attending the APCaRI Fall Symposium 2022!

The APCaRI Fall Symposium 2022, held November 18-19, was a huge success! We thank our keynote speakers Dr. Chris Wallis, Dr. Paul Boutros, and Mr. Vijay Pandurangan for joining us in beautiful Banff, Alberta.  The keynote and APCaRI member speakers gave inspiring and informative talks.

We are especially appreciative of the participants representing patient advocacy groups, urologists, oncologists, funders, clinicians, trainees, and researchers who engaged in lively and productive conversation!

This year APCaRI also celebrated the many years of service from outgoing APCaRI Co-chairs Drs John Lewis and Eric Hyndman and welcomed incoming Co-chairs, Drs Adam Kinnaird, and Steven Yip.

Thank you again to our sponsors Astellas, AstraZeneca, Bayer, Janssen, Merck, and Pfizer who made this symposium possible.

APCaRI looks forward to seeing all of you again soon!

 

- Perrin Beatty